Medicus Pharma's SKNJCT-004 Trial Begins Enrolling Participants in UAE

Medicus Pharma has started its Phase 2 BCC trial in the UAE, enrolling 36 patients across four medical centers. The trial aims to assess the efficacy of its investigational therapy D-MNA compared to a placebo control. The company's broader clinical program targeting BCC continues to advance, with its SKNJCT-003 Phase 2 study underway in the US. Medicus Pharma has also acquired UK-based biotech Antev, gaining control of three FDA-approved clinical studies.

Medicus Pharma Ltd. (NASDAQ:MDCX) has made significant progress in its efforts to develop innovative treatments for basal cell carcinoma (BCC) of the skin. The company has recently initiated its Phase 2 clinical study, SKNJCT-004, in the United Arab Emirates (UAE), with the goal of assessing the efficacy of its investigational therapy, D-MNA, compared to a placebo control. The study commenced patient recruitment at Cleveland Clinic Abu Dhabi (CCAD) and is expected to enroll 36 patients across four medical centers in the UAE Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)^[1].

The SKNJCT-004 study is designed as a randomized, double-blind, placebo-controlled, multi-center trial, enrolling up to 36 subjects presenting with BCC of the skin. Participants will be randomized 1:1:1 to one of three groups: a placebo-controlled group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA. The high-dose, 200μg D-MNA, is the maximum dose used in the Company's Phase 1 safety and tolerability study (SKNJCT-001) completed in March 2021 Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)^[1].

Medicus Pharma's broader clinical program targeting BCC continues to advance. The company's SKNJCT-003 Phase 2 clinical study is currently underway in nine clinical sites across the United States and Europe. As of August 2025, SKNJCT-003 has randomized more than 75% of the 90 participants expected to be randomized in the study Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)^[1].

In addition to its clinical trials, Medicus Pharma has also expanded its portfolio through strategic acquisitions. In August 2025, the company completed the acquisition of Antev Limited, a UK-based late clinical stage biotech company developing Teverelix, a next-generation GnRH antagonist for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)^[1].

The acquisition of Antev provides Medicus Pharma with control over three FDA-approved clinical studies, including a Phase 2b study design for advanced prostate cancer and acute urinary retention. The FDA has provided written guidance on the proposed Phase 3 trial design for Teverelix, supporting the Company's clinical plans to develop the drug for advanced prostate cancer patients with increased cardiovascular risk Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)^[1].

Medicus Pharma's progress in its clinical programs and strategic acquisitions underscores the company's commitment to advancing innovative treatments for various medical conditions. The company's ongoing Phase 2 studies, including SKNJCT-004 in the UAE and SKNJCT-003 in the US and Europe, aim to bring novel, non-invasive alternatives to market for the treatment of BCC and other conditions.